Tarsus Pharmaceuticals Inc

+0.18 (+1.13%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)434.81M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$10 Million
Adjusted EPS-$0.74
See more estimates
10-Day MA$15.54
50-Day MA$15.48
200-Day MA$15.67
See more pivots

Tarsus Pharmaceuticals Inc Stock, NASDAQ:TARS

15440 Laguna Canyon Road, Suite 160, Irvine, California 92618
United States of America
Phone: +1.949.409.9820
Number of Employees: 46


Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.